Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Sarepta Therapeutics, Inc. - Common Stock
(NQ:
SRPT
)
16.23
+0.14 (+0.87%)
Streaming Delayed Price
Updated: 4:00 PM EST, Mar 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sarepta Therapeutics, Inc. - Common Stock
< Previous
1
2
...
14
15
16
17
18
19
20
21
22
...
34
35
Next >
Sarepta Therapeutics' Duchenne Gene Therapy Shows Sustained Benefits And Disease Stabilization At Two Years
↗
January 27, 2025
Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits, including motor function improvement and minimal muscle pathology progression.
Via
Benzinga
Sarepta Therapeutics Announces Results from Part 2 of the EMBARK Study Demonstrating Sustained Benefits and Disease Stabilization in Ambulatory Individuals with Duchenne Muscular Dystrophy Following Treatment with ELEVIDYS
January 27, 2025
From
Sarepta Therapeutics, Inc.
Via
Business Wire
What 14 Analyst Ratings Have To Say About Sarepta Therapeutics
↗
January 15, 2025
Via
Benzinga
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product Revenue
January 13, 2025
From
Sarepta Therapeutics, Inc.
Via
Business Wire
A Glimpse Into The Expert Outlook On Sarepta Therapeutics Through 15 Analysts
↗
December 19, 2024
Via
Benzinga
Analyst Expectations For Sarepta Therapeutics's Future
↗
November 25, 2024
Via
Benzinga
Peeling Back The Layers: Exploring Sarepta Therapeutics Through Analyst Insights
↗
October 21, 2024
Via
Benzinga
Solid Biosciences Outpaces Competitors In Duchenne Gene Therapy Development
↗
January 08, 2025
Solid Biosciences advances gene therapies for muscular and cardiac diseases, gaining FDA clearance for SGT-212 and targeting key 2025 milestones.
Via
Benzinga
Sarepta Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 06, 2025
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 31, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
December 18, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Unveiling 15 Analyst Insights On Sarepta Therapeutics
↗
October 21, 2024
Via
Benzinga
Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst
↗
December 13, 2024
Wedbush initiates Solid Biosciences with an Outperform rating, citing the potential of SGT-003 for Duchenne muscular dystrophy and a robust cash runway.
Via
Benzinga
Archer Aviation, Hims & Hers Health And Urban Outfitters Are Among Top 8 Mid-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?
↗
December 01, 2024
8 mid-cap stocks saw impressive gains last week. Archer, Scholar Rock, Arrowhead, Iris Energy, Hims & Hers, SoundHound, Joby Aviation, and Urban Outfitters all performed well.
Via
Benzinga
Rivian Automotive, Rocket Lab And Moderna Are Among Top 10 Large-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?
↗
December 01, 2024
Top performers last week: RIVN, RKLB, SRPT, EXAS, ESTC, ULTA, MRNA, RL, CPRT, SNAP. Any in your portfolio? Citigroup raises price target on ULTA and SNAP.
Via
Benzinga
Wall Street's Top 10 Stock Calls This Week - Saturday, Nov. 30
↗
November 30, 2024
Via
Talk Markets
Topics
Stocks / Equities
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 29, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Shares Are On The Rise Today: What's Going On?
↗
November 26, 2024
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global licensing and collaboration agreement with Sarepta Therapeutics Inc. (NASDAQ: SRPT)....
Via
Benzinga
J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
↗
November 26, 2024
Via
Benzinga
Arrowhead Launches 25% On A Massive Licensing Deal With Sarepta
↗
November 26, 2024
The deal focuses on four clinical-stage drugs, three preclinical assets and a potential five new targets.
Via
Investor's Business Daily
Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs
November 26, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
↗
November 25, 2024
Via
Benzinga
Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday
↗
November 07, 2024
Via
Benzinga
This McKesson Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
↗
November 07, 2024
Via
Benzinga
Sarepta Therapeutics (SRPT) Q3 2024 Earnings Call Transcript
↗
November 07, 2024
SRPT earnings call for the period ending September 30, 2024.
Via
The Motley Fool
Topics
Earnings
Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate Developments
November 06, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 31, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results
October 23, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
↗
October 21, 2024
Via
Benzinga
After US Senator, Unions Urge Federal Trade Commission To Block Novo's $16.5B Acquisition Of Catalent
↗
October 18, 2024
Public interest groups are urging the FTC to block Novo Holdings' $16.5 billion acquisition of Catalent, citing concerns over reduced competition in critical areas like diabetes, obesity treatments,...
Via
Benzinga
< Previous
1
2
...
14
15
16
17
18
19
20
21
22
...
34
35
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
